| Literature DB >> 31384808 |
Deepika Sharma1, Sanjiv Kumar1, Balasubramanian Narasimhan1, Kalavathy Ramasamy2,3, Siong Meng Lim2,3, Syed Adnan Ali Shah2,4, Vasudevan Mani5.
Abstract
In order to overcome the challenges of microbial resistance as well as to improve the effectiveness and selectivity of chemotherapeutic agents against cancer, a novel series of 4-(4-bromophenyl)-thiazol-2-amine derivatives was synthesized and its molecular structures were confirmed by physicochemical and spectral characteristics. The synthesized compounds were further evaluated for their in vitro antimicrobial activity using turbidimetric method and anticancer activity against oestrogen receptor positive human breast adenocarcinoma cancer cell line (MCF7) by Sulforhodamine B (SRB) assay. The antimicrobial activity results revealed that compound p2, p3, p4 and p6 exhibited promising antimicrobial activity that are comparable to standard norfloxacin (antibacterial) and fluconazole (antifungal). Anticancer screening results demonstrated that compound p2 was found to be the most active one against cancer cell line when compared to the rest of the compounds and comparable to the standard drug (5-fluorouracil). The molecular docking study demonstrated that compounds, p2, p3, p4 and p6 displayed good docking score within binding pocket of the selected PDB ID (1JIJ, 4WMZ and 3ERT) and showed promising ADME properties.Entities:
Keywords: Anticancer; Antimicrobial; Molecular docking; Synthesis; Thiazole derivatives
Year: 2019 PMID: 31384808 PMCID: PMC6661755 DOI: 10.1186/s13065-019-0575-x
Source DB: PubMed Journal: BMC Chem ISSN: 2661-801X
Fig. 1Marketed preparation of thiazole nucleus
Fig. 2Design of proposed thiazole molecules for antimicrobial and anticancer potential based on literature
Scheme 1For the synthesis of 4-(4-bromophenyl)thiazol-2-amine derivatives (p1–p10)
Physicochemical properties of the synthesized compounds (p1–p10)
| S. no | Compound | Molecular formula | Color | m.pt. °C | R | % Yield | |
|---|---|---|---|---|---|---|---|
| 1 |
|
4-(4-Bromophenyl)- | C18H15N2SBrO2 | Light yellow | 134–136 | 0.45 | 85 |
| 2 |
|
4-((4-(4-Bromophenyl)thiazol-2-ylimino)methyl)-2-methoxyphenol | C17H13N2SBrO2 | Creamy yellow | 122–125 | 0.38 | 70 |
| 3 | ( |
4-(4-Bromophenyl)- | C18H16N3SBr | Yellowish white | 117–120 | 0.25 | 65 |
| 4 |
|
| C19H17N2SBrO3 | Greenish yellow | 105–107 | 0.30 | 75 |
| 5 |
|
| C16H10N2SBr2 | Dark yellow | 62–64 | 0.38 | 69 |
| 6 |
|
1-((4-(4-Bromophenyl)thiazol-2-ylimino)methyl)naphthalen-2-ol | C20H13BrN2OS | Light yellow | 105–107 | 0.30 | 72 |
| 7 |
|
| C16H10BrClN2S | Light yellow | 65–70 | 0.23 | 83 |
| 8 |
|
| C18H15BrN2O2S | Lemon yellow | 71–73 | 0.52 | 72 |
| 9 |
|
| C17H13BrN2OS | Yellowish white | 188–190 | 0.79 | 65 |
| 10 |
|
3-(((4-(4-Bromophenyl)thiazol-2-yl)imino)methyl)phenol | C16H11BrN2OS | Dark yellow | 106–108 | 0.21 | 71 |
Spectral data of the synthesized compounds and intermediate (Int.)
| Sr. no. | IR KBr (cm−1) | 1H-NMR (DMSO-d6, ppm) | 13C-NMR (DMSO-d6, ppm) | MS: | Elemental analysis (CHN) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| C=C str. | C–Br str. | C–O–C str. OCH3 | C–S str. | C=N str. | Other (str./bending) | |||||
| Int. | 1586 | 666 | – | 725 | 1632 | 817 (N–H str., NH2), 1265 (C–N str., Ar–NH2) | 7.19–7.56 (m, 4H, ArH), 6.90 (s, 1H, CH of thiazole), 4.12 (s, 2H, –NH2 of thiazole) | 127.4, 131.1, 122.6, 130.2, 127.3, 130.8 (6C, phenyl nucleus), 167.7, 100.4, 151.5 (3C, thiazole) | 255 | Theoretical calc: C, 42.37; H, 2.77; N, 10.98; Found: C, 42.31; H, 2.74; N, 10.89 |
|
| 1587 | 642 | 1266 | 725 | 1674 | – | 6.93 (m, 7H, aromatic H), 7.42 (s, 1H, CH of thiazole) | 120.4, 109.4, 128.7, 122.2, 110.3, 150.87, 123.2, 110.0, 150.2, 110.6, 148.5, 128.6 (12C, phenyl nucleus), 150.3, 172.41, 109.6 (3C, thiazole), 159.4 (N=CH), 55.2, 54.6 (2C, OCH3) | 404 | Theoretical calc: C, 53.61; H, 3.75; N, 6.95; Found: C, 53.48; H, 3.69; N, 6.81 |
|
| 1590 | 601 | 1208 | 756 | 1673 | – | 6.76–7.45 (m, 7H, ArH), 7.43 (s, 1H, C–H of thiazole), 8.85 (s, 1H, N=CH), 3.71 (s, 3H, OCH3), 5.39 (s, 1H, OH) | 130.4, 127.4, 124.7, 132.1, 130.3, 131.8, 119.8, 115.4, 150.2, 147.6, 113.4, 127.9, (12C, phenyl nucleus), 151.3, 173.1, 108.6 (3C, thiazole), 158.2 (N=CH), 55.7 (O–CH3), 53.4 (1C, –OCH3) | 390 | Theoretical calc: C, 52.45; H, 3.37; N, 7.20; Found: C, 52.33; H, 3.41; N, 7.18 |
|
| 1588 | 726 | 1229 | 812 | 1658 | 830 [(C–N str., N(CH3)2] | 6.80–7.41 (m, 8H, ArH), 7.80 (s, 1H, –N=CH), 3.43 (s, 3H, OCH3), 7.45 (s, 1H, CH of thiazole) | 130.4, 127.4, 124.7, 132.1, 130.3, 131.8, 124.6, 129.1, 110.8, 152.2, 110.8, 127.3 (12C, phenyl nucleus), 151.3, 173.41, 108.6 (3C, thiazole), 158.2 (N=CH), 40.8, 39.9 (2C, N(CH3)2) | 375 | Theoretical calc: C, 57.00; H, 4.53; N, 10.50; Found: C, 57.04; H, 4.42; N, 10.47 |
|
| 1588 | 575 | 1232 | 705 | 1682 | 1325 (C–O str. and O–H in plane bending, phenol) | 6.9–7.39 (m, 6H, ArH), 7.73 (s, 1H, –N=CH), 3.73 (s, 3H, OCH3), 7.47 (s, 1H, CH of thiazole), 2.91 (s, 6H, N(CH3)2) | 121.5, 107.2, 128.7, 123.1, 111.1, 151.2, 151.1, 102.3, 130.1, 103.1, 152.1, 140.5 (12C, phenyl nucleus), 149.3, 171.2, 109.8 (3C, thiazole), 160.1 (N=CH), 59.6, 55.8 (2C, OCH3, 54.3, 58.5 (2C, OCH3) | 422 | Theoretical calc: C, 52.66; H, 3.95; N, 6.46; Found: C, 52.54; H, 3.87; N, 6.44 |
|
| 1587 | 589 | – | 829 | 1677 | – | 7.28–7.60 (m, 8H, ArH), 7.90 (s, 1H, N=CH), 7.49 (s, 1H, CH of thiazole) | 120.1, 126.7, 123.1, 111.1, 151.2, 109.2, 130.1, 126.2, 131.2, 122.8, 129.7, 128.6, 131.2 (12C, phenyl nucleus), 149.3, 171.2, 109.8 (3C, thiazole), 160.1 (N=CH), 59.6 (C, –OCH3) | 423 | Theoretical calc: C, 45.52; H, 2.39; N, 6.64; Found: C, 45.48; H, 2.27; N, 6.51 |
|
| 1590 | 592 | – | 742 | 1618 | 1395 (C–O str. and O–H in plane bending, phenol), | 7.36–8.01 (m, 10H, ArH), 8.14 (s, 1H, N=CH), 7.43 (s, 1H, CH of thiazole) | 122.6, 126.7, 132.1, 118.1, 151.2, 128.21, 131.4, 119.5, 170.5, 107.9 (12C, naphthalene nucleus), 148.3, 169.1, 109.1 (3C, thiazole), 159.10 (N=CH) | 410 | Theoretical calc: C, 58.69; H, 3.20; N, 6.84; Found: C, 58.55; H, 3.18; N, 6.83 |
|
| 1590 | 607 | – | 829 | 1521 | 725 (C–Cl str., ArCl) | 7.24–7.58 (m, 8H, ArH), 7.90 (s, 1H, N=CH), 7.43 (s, 1H, CH of thiazole) | 127.2, 129.4, 134.5, 129.8, 135.6, 126.3, 129.8, 133.2, 131.4, 124.8, 135.5 (12C, phenyl nucleus), 149.5, 173.2, 108.8 (3C, thiazole), 159.1 (N=CH) | 380 | Theoretical calc: C, 50.88; H, 2.67; N, 7.4; Found: C, 50.76; H, 2.51; N, 7.2 |
|
| 1583 | 572 | 1263 | 720 | 1675 | – | 6.80–7.35 (m, 7H, ArH), 7.90 (s, 1H, N=CH), 7.36 (s, 1H, CH of thiazole), 3.88 (s, 1H, OCH3) | 124.2, 134.5, 130.2, 133.5, 128.8, 104.5, 132.1, 115.1, 158.3, 100.2, 161.8 (12 C, phenyl nucleus), 149.5, 173.2, 108.8 (3C, thiazole), 161.2 (N=CH), 54.6, 53.5 (2C, OCH3) | 404 | Theoretical calc: C, 53.61; H, 3.75; N, 6.95; Found: C, 53.59; H, 3.64; N, 6.81 |
|
| 1532 | 659 | 1265 | 805 | 1583 | – | 6.90–7.27 (m, 8H, ArH), 7.40 (s, 1H, N=CH), 7.38 (s, 1H, CH of thiazole), 3.90 (s, 1H, OCH3) | 125.2, 133.5, 131.2, 127.5, 126.8, 127.6, 120.1, 136.5, 110.1, 159.7 (12C, phenyl nucleus), 151.5, 172.3, 107.6 (3C, thiazole), 160.2 (N = CH), 54.3 (O-CH3) | 374 | Theoretical calc: C, 54.70, H, 3.51; N, 7.50; Found: C, 54.56; H, 3.28; N, 7.38 |
|
| 1505 | 720 | 1265 | 829 | 1583 | 1397 (C–O str. and O–H in plane bending, phenol) | 6.70–7.38 (m, 8H, ArH), 9.70 (s, 1H, N=CH), 7.52 (s, 1H, CH of thiazole) | 127.2, 132.5, 130.2, 126.5, 125.8, 115.2, 157.3, 112.2, 136.5, 120.0, 131.1 (12C, phenyl nucleus), 150.5, 171.3, 108.5 (3C, thiazole), 160.1 (N=CH) | 360 | Theoretical calc: C, 53.49; H, 3.09; N, 7.80; Found: C, 53.41; H, 3.07; N, 7.72 |
Antimicrobial and anticancer screening results of synthesized thiazole molecules (p1–p10)
| Compound | (Antimicrobial screening) MIC = µM | aIC50 = µM | ||||
|---|---|---|---|---|---|---|
| Microbial species | ||||||
| Bacterial | Fungal | Cancer cell line | ||||
|
|
|
|
|
| MCF7 | |
|
| 31 | 62.0 | 31 | 31 | 31 | 17.4 |
|
| 16.1 | 32.1 | 16.1 | 32.1 | 32.1 | 10.5 |
|
| 32.4 | 32.4 | 32.4 | 32.4 | 16.2 | 37.4 |
|
| 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 38.0 |
|
| 29.6 | 29.6 | 29.6 | 29.6 | 29.6 | 40.3 |
|
| 30.5 | 30.5 | 30.5 | 15.3 | 30.5 | 73.3 |
|
| 33.1 | 33.1 | 33.1 | 16.5 | 33.1 | 47.6 |
|
| 31 | 31.0 | 62.0 | 15.5 | 62.0 | 52.1 |
|
| 33.5 | 67.0 | 67.0 | 33.5 | 33.5 | 17.2 |
|
| 17.4 | 34.8 | 34.8 | 34.8 | 34.8 | 21.4 |
| Norfloxacin | 4.7 | 4.7 | 4.7 | – | – | – |
| Fluconazole | – | – | – | 5.0 | 5.0 | – |
| 5-Fluorouracil | – | – | – | – | – | 5.2 |
S.A.: Staphylococcus aureus (MTCC3160); B.S.: Bacillus subtilis (MTCC441); E.C.: Escherichia coli (MTCC443); C.A.: Candida albicans (MTCC227) and A.N.: Aspergillus niger (MTCC281)
aIC50 is the concentration required to inhibit 50% of cell growth
Fig. 3Graphical representation of antibacterial activity of synthesized compounds
Fig. 4Graphical representation of antifungal activity of synthesized compounds
Fig. 5Graphical representation of anticancer activity of synthesized compounds
Fig. 6Pictorial presentation (3D) and Ligand interaction diagram (2D) of most active antibacterial compounds (p2, p3 and p4) and standard norfloxacin
Docking results of most active (antibacterial and antifungal) compounds and standard drugs
| Compound | Docking score | Glide energy (kcal/mol) | Interacting amino acid residues |
|---|---|---|---|
|
| − 5.547 | − 49.479 | Asp177, Gln174, Tyr36, Cys37, Ala39, Asp40, Thr42, Lys84, Gly83, Ser82, Asp80 |
|
| − 6.513 | − 48.914 | His468, Cys470, Phe463, Leu380, Pro379, Hie378, Thr322, Ser319, Tyr126 |
|
| − 4.845 | − 54.654 | His47, Gly49, Hie50, Pro53, Gln174, Asp177, Ile200, Asn199, Gln196, Asp195, Gly193, Gly192 |
|
| − 8.342 | − 45.842 | Tyr126, Leu129, Thr130, Tyr140, Ile139, Cys470, Thr322, Ser319, Thr318 |
|
| − 6.18 | − 53.349 | Asp177, Glu174, Leu70, Tyr36, Cys37, Gly38, Ala39, Asp40, Gln190, Val191, Gly192 |
|
| − 5.847 | − 40.932 | His468, Arg469, Cys470, Ile471, Tyr126, Hie378, Leu380, Leu383, Arg385 |
Fig. 7Pictorial presentation (3D) and ligand interaction diagram (2D) of most active antifungal compounds (p3 and p6) and standard fluconazole
Fig. 8Pictorial presentation (3D) and ligand interaction diagram (2D) of most active compound (p2) and standard 5-fluorouracil
Docking results of most active anticancer compound p2 with standard drug
| Compound | Docking score | Glide energy (kcal/mol) | Interactive residues |
|---|---|---|---|
|
| − 6.732 | − 42.44 | Trp383, Leu384, Leu387, Met388, Leu391, Phe404, Met343, Leu346, Met347 |
|
| − 3.414 | − 24.58 | Glu353, Ala350, Leu349, Leu346, Leu348, Leu387, Met388, Phe404, Leu391, Arg394 |
ADME parameters of most active antimicrobial and anticancer compounds
| Comp. | Molecular structure | ADME parameters | |||||
|---|---|---|---|---|---|---|---|
| Mol MW | QPlogPo/w | DonorHB | AccptHB | Percent human oral absorption | Rule of five | ||
|
|
| 389.266 | 4.607 | 1.0 | 4.0 | 100.0 | 0 |
|
|
| 400.335 | 5.71 | 0.0 | 3.5 | 100.0 | 1 |
|
|
| 433.319 | 5.447 | 0.0 | 4.75 | 100.0 | 1 |
|
|
| 409.299 | 5.52 | 1.0 | 3.25 | 100.0 | 1 |
Fig. 9Structural activity relationship of synthesized thiazole derivatives